News
-
TIF’s NEW e-COURSE | Enhance Your Understanding of EU Health Policy
To address this need, the Thalassaemia International Federation (TIF) has launched an e-course titled ‘EU Health Policy Course’, which offers a comprehensive and up-to-the-minute overview of EU health-related policies. The…
Read More » -
TIF2023 | 16th International Conference on Thalassaemia & Haemoglobinopathies, November 3-5
The Conference, organized in collaboration with the Federation of Malaysia Thalassaemia Societies, the Malaysia Hematology Society and the Malaysian Association of Paediatric Haematology & Oncology, and with the support of…
Read More » -
CLINICAL NEWS | Promising Outcomes Found with Stem Cell Transplant for Fanconi Anemia-related Leukemia, MDS
Two-thirds of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) to treat myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) resulting from Fanconi anemia (FA) were still alive at…
Read More » -
POSITION PAPER | Strengthening the Resilience of EU Health Systems
Thalassaemia is more than just a rare condition in Europe; it is a pressing issue that requires prompt action. With shifting migration patterns and escalating healthcare costs, EU health systems…
Read More » -
THAL PALS PODCAST | New Episode on TIF’s NTDT Guidelines Out Now
Dr. Κevin Kuo, MD, MSc, Clinician Investigator, and Μrs. Laurice Levine, Thalassaemia Patient Advocate, talk to TIF’s Executive Director, Dr Androulla Eleftheriou, and Dr. Khaled Musallam, Chief Research Officer, MD,…
Read More » -
Imatinib’s Impact on Reducing Painful Episodes in Sickle Cell Disease
Currently, hydroxyurea (HU) is the only FDA-approved drug highly recommended for treating sickle cell anemia. However, its efficiency varies among patients with sickle cell disease for unknown reasons. Given the…
Read More » -
WEBINAR | Official Launch of TIF’s Nutrition Guidelines in Thalassaemia and PKD
This essential guide has been eagerly awaited by healthcare professionals and patients alike, and we are pleased to invite you to participate in the event. Date: October 13th, 2023 Time:…
Read More » -
BLOOD TRAΝSFUSION THERAPY | FDA Approves Hemanext ONE®
This revolutionary technology sets a new standard in RBC processing and storage by limiting oxygen in the storage environment, thereby providing a higher quality blood product for patients requiring transfusions.…
Read More » -
WEBINAR | Haemoglobin Disorders and EU Health Policies, 21 September 2023
Designed for patients and their families, these webinars aim to foster national advocacy for the improvement of service delivery. The series will encompass all EU legislative files directly or indirectly…
Read More » -
CLINICAL NEWS | FDA Approves Luspatercept for First-line Treatment of Anemia in Lower-Risk MDS
The approval was based on interim results from the pivotal phase 3 COMMANDS trial (ClinicalTrials.gov Identifier: NCT03682536) that evaluated the efficacy and safety of luspatercept in 356 patients with anemia due to international…
Read More »